Debating the True Benefit of Adjuvant TKIs in High-Risk RCC
Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.
Low Recurrence Score in Breast Cancer Shows No Survival Benefit With Chemo Plus Hormonal Therapy
Collective findings from clinical trials show that, for women with early-stage breast cancer who have a low 21-gene recurrence score, adding chemotherapy to standard hormonal therapy does not show a difference in survival.
2 Clarke Drive Cranbury, NJ 08512